Coho Partners Ltd. Sells 138,116 Shares of Cencora, Inc. (NYSE:COR)

Coho Partners Ltd. cut its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 24.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 434,545 shares of the company's stock after selling 138,116 shares during the period. Cencora accounts for about 4.5% of Coho Partners Ltd.'s holdings, making the stock its 3rd biggest position. Coho Partners Ltd. owned 0.22% of Cencora worth $97,634,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Exchange Traded Concepts LLC lifted its position in Cencora by 41.6% during the third quarter. Exchange Traded Concepts LLC now owns 5,334 shares of the company's stock worth $1,201,000 after buying an additional 1,568 shares during the period. Swedbank AB increased its stake in shares of Cencora by 2.3% during the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company's stock valued at $313,863,000 after acquiring an additional 31,104 shares during the last quarter. Sumitomo Life Insurance Co. lifted its holdings in shares of Cencora by 2.8% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 5,049 shares of the company's stock worth $1,136,000 after acquiring an additional 136 shares during the period. Vontobel Holding Ltd. boosted its position in shares of Cencora by 1.4% in the third quarter. Vontobel Holding Ltd. now owns 4,250 shares of the company's stock worth $957,000 after acquiring an additional 58 shares during the last quarter. Finally, Seven Grand Managers LLC purchased a new stake in Cencora in the third quarter valued at approximately $16,881,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Barclays increased their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Evercore ISI upped their price target on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Mizuho started coverage on Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective on the stock. Finally, Robert W. Baird increased their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and an average target price of $277.90.

Cencora Stock Performance

Cencora stock traded down $1.26 during mid-day trading on Tuesday, reaching $241.37. The company's stock had a trading volume of 1,285,039 shares, compared to its average volume of 1,509,704. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $262.26. The business has a 50 day moving average price of $238.75 and a 200-day moving average price of $237.41. The firm has a market cap of $46.65 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Sell-side analysts predict that Cencora, Inc. will post 15.36 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Friday, February 14th. Cencora's payout ratio is 31.29%.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.